整理 | GLP1减重宝典内容团队3月6日,国家药监局官网信息显示,诺和诺德的依柯胰岛素司美格鲁肽注射液 IcoSema 在中国获批上市,用于2型糖尿病治疗。它的特殊之处在于,这不是一款单一成分的降糖药,而是一支把超长效基础胰岛素与长效GLP-1受体激动剂合在一起的复方制剂,目标指向的是当前糖尿病管理里最现实的矛盾:既要把HbA1c压下去,又要尽量减少体重负担和治疗复杂度。IcoSema由两种活性...
Source Link整理 | GLP1减重宝典内容团队3月6日,国家药监局官网信息显示,诺和诺德的依柯胰岛素司美格鲁肽注射液 IcoSema 在中国获批上市,用于2型糖尿病治疗。它的特殊之处在于,这不是一款单一成分的降糖药,而是一支把超长效基础胰岛素与长效GLP-1受体激动剂合在一起的复方制剂,目标指向的是当前糖尿病管理里最现实的矛盾:既要把HbA1c压下去,又要尽量减少体重负担和治疗复杂度。IcoSema由两种活性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.